JPWO2021138025A5

JPWO2021138025A5 -

Info

Publication number: JPWO2021138025A5
Application number: JP2022539396A
Authority: JP
Publication date: 2023-12-14
Anticipated expiration: 2040-12-11

Description

いくつかの実施形態において、患者の舌の上で速やかに溶解する溶解性フィルムまたは口腔内薬物ストリップを含む組成物が提供される。いくつかの例において、溶解性フィルムは、塩化ナトリウムと、例えばクエン酸などの酸味剤とを含むポリマーである。いくつかの例において、溶解性フィルムは、ストリップを形成するポリマー、可塑剤、甘味料、唾液を刺激する薬剤、香料、着色料、安定化剤、粘稠化剤、および他の適切な賦形剤からなる群から選択された１つ以上の賦形剤をさらに含み、この賦形剤は、経口医薬品の投与剤形で使用するのに適している。 In some embodiments, compositions are provided that include a dissolvable film or buccal drug strip that quickly dissolves on a patient's tongue. In some examples, the dissolvable film is a polymer that includes sodium chloride and an acidulant, such as citric acid. In some instances, the dissolvable film contains strip-forming polymers, plasticizers, sweeteners, saliva-stimulating agents, flavoring agents, colorants, stabilizers, thickening agents, and other suitable excipients. and one or more excipients selected from the group consisting of agents, which excipients are suitable for use in oral pharmaceutical dosage forms.

いくつかの実施形態において、咽頭反射を予防する、または抑制する方法が提供され、この方法は、患者の口腔にアクセスする直前に、本発明の組成物を患者の舌に適用する工程を含む。組成物が粉末形態で提供される実施形態において、組成物は、アプリケータを濡らした後、粉末組成物と接触させることによって患者の舌に適用してもよく、ここで、アプリケータの濡らされた状態が、治療量の粉末組成物を濡れたアプリケータに付着することをもたらす。その後、濡れたアプリケータ、および付着した粉末組成物は、患者の舌に適用される。いくつかの実施形態において、アプリケータは、舌圧子、綿棒、手袋をはめた指、または患者の手袋をはめていない指の少なくとも１つを含む。いくつかの実施形態において、粉末組成物の計量部分は、患者の舌に直接適用される。

In some embodiments, a method of preventing or suppressing the gag reflex is provided, the method comprising applying a composition of the invention to the tongue of a patient immediately prior to accessing the patient's oral cavity. In embodiments where the composition is provided in powder form, the composition may be applied to the patient's tongue by wetting an applicator and then contacting the powder composition, where the wetting of the applicator The condition results in depositing a therapeutic amount of the powder composition onto the wet applicator. The wet applicator and attached powder composition are then applied to the patient's tongue. In some embodiments, the applicator includes at least one of a tongue depressor, a cotton swab, a gloved finger, or an ungloved finger of the patient. In some embodiments, a measured portion of the powder composition is applied directly to the patient's tongue.

Claims

A composition for controlling the gag reflex in a patient, the composition comprising sodium chloride and citric acid in a 3:1 volume ratio and in powder form.

A method for controlling the gag reflex in a patient, the method comprising:
providing a composition consisting essentially of sodium chloride and citric acid in a 3:1 volume ratio, and
administering the therapeutic amount of the composition to the patient by contacting the upper surface of the patient's tongue with the therapeutic amount of the composition;
including;
A method, wherein the composition is in powder form.

3. The method of claim 2, comprising delaying oral treatment until a delay of less than 20 seconds after administering the therapeutic amount of the composition to the patient.

3. The method of claim 2, comprising commencing oral treatment within 12 hours after administering the therapeutic amount of the composition to the patient.

A method for controlling the gag reflex in a patient, the method comprising:
providing a composition consisting essentially of sodium chloride and citric acid in a 3:1 volume ratio;
the process of wetting the applicator,
depositing a therapeutic amount of the composition on the wetted applicator by contacting the composition with the wetted applicator;
administering the therapeutic amount of the composition to the patient by contacting the upper surface of the patient's tongue with the moistened applicator and the therapeutic amount of the composition deposited thereon;
including methods.

6. The method of claim 5, comprising delaying oral treatment until a delay of less than 20 seconds after administering the therapeutic amount of the composition to the patient.

6. The method of claim 5, comprising commencing oral treatment within 12 hours after administering the therapeutic amount of the composition to the patient.

6. The method of claim 5, wherein the composition is in powder form.

6. The method of claim 5, wherein wetting the applicator includes applying the applicator to the patient's tongue.

6. The method of claim 5, wherein the step of wetting the applicator includes wetting the applicator with saliva of the patient.

6. The method of claim 5, wherein the applicator is selected from the group consisting of a tongue depressor, a cotton swab, a gloved finger, and an ungloved patient finger.